the sackler · purdue · oxycontin
entry · 1996–ongoing · status: archived (litigation ongoing) · ~900,000 dead
summary
Purdue Pharma — owned by the Sackler family — launched OxyContin in 1996 with a marketing claim that, due to its time-release formulation, the drug had a "less than 1% addiction rate." Internal company documents later disclosed in litigation showed the Sacklers and Purdue executives knew the addiction risk was substantially higher than that figure, were warned by their own scientists in the 1990s, and pushed the marketing campaign forward anyway. By 2024, the cumulative U.S. death toll from prescription and illicit opioids since 1999 had crossed approximately 900,000 people.
the playbook
- 1996 launch. Aggressive sales force targeting general practitioners (not just pain specialists). Tens of thousands of free samples. All-expense-paid "pain management" conferences at resorts.
- Doctored statistics. The "less than 1%" addiction figure traced back to a five-sentence 1980 letter to the editor of the New England Journal of Medicine describing hospitalized inpatients on short-term opioids — not chronic outpatient prescription users. Purdue's marketing cited it as if it were a definitive study.
- Consultant support. McKinsey & Co. advised Purdue from 2004 onward on how to "turbocharge" sales of OxyContin, including proposing rebates to distributors for overdose deaths to motivate continued ordering. (McKinsey paid ~$641M to settle related state suits in 2021; senior partners destroyed records to avoid disclosure.)
- The 2007 plea. Purdue and three executives pled guilty in 2007 to misbranding OxyContin and paid $634M. The Sacklers personally were not charged. The company continued the marketing campaign.
extraction during the bankruptcy
Between 2008 and 2018, with litigation visibly approaching, the Sacklers extracted approximately $11 billion from Purdue Pharma to family-controlled offshore trusts. By the time Purdue filed for Chapter 11 in 2019, the operating company was under-capitalized to settle the claims against it. The original 2024 bankruptcy plan offered ~$6 billion from the Sacklers in exchange for blanket immunity from all civil claims — including claims from victims who had not consented to release them.
the supreme court reversal · 2024
Harrington v. Purdue Pharma, decided June 27, 2024 in a 5-4 ruling. Justice Neil Gorsuch, writing for the majority, held that bankruptcy law does not permit non-consensual third-party releases — i.e., the Sacklers could not use Purdue's bankruptcy to extinguish claims against them personally. The settlement was thrown out.
the new settlement · 2025
A revised settlement of $7.4 billion, announced January 2025 and confirmed through the courts, became the largest individual-pay opioid settlement on record. The Sacklers will pay $1.5B in the first installment, with $500M after one year, $500M after two years, $400M after three years. The family retains billions extracted before the bankruptcy and faces no criminal prosecution.
why this matters to PRIOR
The Sackler arc is the cleanest 21st-century expression of the architecture: a family enriched itself by manufacturing addiction at population scale, was warned by its own experts, ignored the warnings, extracted the proceeds during the litigation window, and shielded its remaining assets behind legal mechanisms. The Supreme Court's 2024 ruling was a partial reversal — but only because the immunity attempt was unprecedentedly brazen. The underlying mechanism (extraction during the litigation window into structures that survive the corporate entity) is fully intact and replicated across other industries.
"the family marketed an addictive drug as non-addictive for two decades. they kept enough of the money to fight the lawsuits with."